A Case of Idiopathic Renal Hypouricemia with SLC22A12 Gene Mutation Showing General Weakness and Incidental Renal Stone

Article information

Child Kidney Dis. 2021;25(1):44-48

Publication date (electronic) : 2021 June 30

doi : https://doi.org/10.3339/jkspn.2021.25.1.44

Jin Woon Joung, M.D., Young Wha Song, M.D., Jong Dae Kim, M.D., Eun Jung Cheon, M.D.

Department of Pediatrics, Konyang University College of Medicine, Daejeon, Korea

Corresponding author: Eun Jung Cheon, M.D. Department of Pediatrics, Konyang University College of Medicine, 158 Gwanjeodong-ro, Seo-gu,Daejeon 35365, Korea Tel: +82-42-600-9230 Fax: +82-42-600-9090 E-mail: ejcheon000@gmail.com

Received 2021 April 8; Revised 2021 June 5; Accepted 2021 June 11.

Abstract

Introduction

Idiopathic renal hypouricemia (iRHUC) is characterized by impaired uric acid transport, reabsorption insufficiency, or accelerated secretion of uric acid [1,2]. There are two types of iRHUC according to two different genetic mutations. A Mutation of SLC22A12 gene encoding a renal urate-anion exchanger (URAT1) causes iRHUC type 1 while a mutation of SLC2A9 gene encoding a glucose and urate transporter (GLUT9) leads to iRHUC type 2 [3]. Since symptoms of iRHUC are mostly mild or nonspecific, diagnosis is usually made after complications have developed [4]. Occasionally hematuria, nephrolithiasis, or exercise- or dehydration-induced acute kidney injury (AKI) could be initial symptoms [5,6]. Symptomatic iRHUCs are known to be relatively more frequent in homozygous SLC2A9 mutations than SLC22A12 mutations. We present a case of a 7-year-old boy who was diagnosed iRHUC with SLC22A12 mutations by hypouricemia and unexpected renal stone.

Case report

A 7-year-old boy visited the outpatient clinic due to persisting dizziness and general weakness from a few years ago. He was born out of normal vaginal delivery and his past medical history since birth was nonspecific except for an event of gross hematuria when he was 7-month-old. But urinalysis at the time showed no hematuria and the symptom never recurred. At his first visit, height was 132 cm (75th percentile), weight 26 kg (25–50th percentile), and BMI 14.9 kg/m² (10–25th percentile). His vital signs were normal. However, dizziness and general weakness had been aggravated nearly to syncope that the patient was frequently absent from school. Otherwise, there were no specific symptoms and physical examination also showed no abnormal findings including costovertebral angle tenderness. Laboratory findings were Hb of 11.9 g/dL (normal range; 11.0–16.0 g/dL), blood urea nitrogen of 14.7 mg/dL (5.0–18.0 mg/dL), creatinine of 0.53 mg/dL (0.22–0.59 mg/ dL), and serum sodium of 137 mmol/L (134–143 mmol/L). The following parameters were within normal limits: renin, aldosterone, and thyroid function test. However, serum uric acid level was 0.85 mg/dL (normal range; 2.0–5.0 mg/ dL), which is abnormally low. Repeated test of uric acid consistently showed low level (0.62 mg/dL). A sequential spot urine test revealed urine uric acid to creatinine ratio (U_UA/U_Cr) of 0.58 but fractional excretion of uric acid (FEUA) of 48.6% (normal range; <10%). Microscopic hematuria was not found on urinalysis. Kidney sonography showed parapelvic high echogenicity and a 4 mm-sized calyceal stone in the left kidney without hydronephrosis (Fig. 1). To identify the underlying cause of the hypouricemia, diagnostic exome sequencing (DES) was performed by Green Cross Genome Corp. using Celemics G-Mendeliome DES kit. Genomic DHA sequencing of the entire coding region of the SLC22A12 was conducted using polymerase chain reaction and the amino acid 258 (tryptophan, TGG) was replaced with a stop codon (TGA) by mutation of G774A [W258X]. The patient was diagnosed a homozygous mutation in the SLC22A12 gene, which is known to be a pathogenic variant of iRHUC (Fig. 2). Accordingly, a whole family including the patient’s mother, father, and brother completed DES. The results revealed that his mother and father had heterozygous mutations of the SLC22A12 gene, the amino acid 258 (TGG) replaced with TGA, while his brother had no mutation (Fig. 3). The patient’s mother was the only one who had a clinical symptom nonspecific as fatigue. Laboratory findings of her showed low level of serum uric acid, 2.2 mg/dL (normal range 2.6–7.2 mg/dL), and high level of FEUA (18.6%). Serum uric acid levels of the patient’s father and brother were 4.35 and 4.25 mg/dL, respectively. FEUA of them were 20.4% and 10.4%, each (Table 1). The patient was advised to avoid intense physical activity and dehydration. He has been on conservative management with potassium citrate for a month now and symptoms are similar so far. Also, he is on yearly follow-up, checking serum and urine uric acid level, and kidney sonography.

Fig. 1.

The kidney sonography of patient shows a renal stone and high echogenicity. A, Calyceal stone* sized (4 mm in size) without hydronephrosis; B, increased echogenicity in parapelvic region.

Fig. 2.

Sequences around the c.774G>A (p.W258X) mutation of the patient and his parents. The black points indicates 774G>A.

Fig. 3.

Sequences around the c.774G>A (p.W258X) mutation of the patient and his brother. His brother had no mutation. The black points indicates 774G>A.

Table 1.

The laboratory findings of the patients and his family

Discussion

Hypouricemia is caused by diminished uric acid production or increased uric acid clearance [7]. iRHUC, also known as familial hypouricemia, is an autosomal recessive disorder characterized by serum uric acid level lower than 2 mg/dL due to increased renal clearance with FEUA above 10% [14]. Genetic analysis of the mutations in SLC22A12 and SLC2A9 is a confirmative test. The impact of SLC2A9 mutations on renal excretion of uric acid is reported exceeding that of SLC22A12 [17]. Therefore, patients with mutations in SLC22A12 tend to show relatively minor symptoms, while those with SLC2A9 mutations represent severe symptoms such as hematuria, nephrolithiasis, or AKI. URAT1, encoded by SLC22A12 , is located on the apical surface of the renal proximal tubule and it regulates urate homeostasis. Mutations on SLC22A12 gene decrease the function of URAT1, which leads to renal hypouricemia type 1 [8-10]. Most of iRHUC cases are caused by the mutation in the SLC22A12 . About half are known to be homozygotes while the rest are compound heterozygotes and heterozygotes in order [14]. Of all reported mutations in SLC22A12 , W258X mutation is a predominant genetic cause of iRHUC in Koreans and Japanese [14].

In Korea, several cases of iRHUC caused by SLC22A12 mutations, showing homozygous W258X, are reported (Table 2) [19]. Only one case, Cheong et al. [14], out of four had no symptoms. One patient showing uricosuria was diagnosed at a young age, and the rest cases were detected late after complications developed. Especially, Kim et al. [19] presented a case of familial renal hypouricemia with repetitive exercised-induced AKI. Repetitive complications including AKI might have been prevented if the first diagnosis of renal hypouricemia was made at a younger age and so that patients were given precautions. Unlike existing reports, in the current case, the patient was young, which could be referred to as a lower chance of exposure to intense physical activity, and without typical symptoms associated with complications. However, nonspecific symptoms such as severe general weakness and the past event of red urine which is now presumed to be uricosuria might have been related to the iRHUC. Even random urine test showed uric acid to creatinine ratio (U_UA/U_Cr) within normal range, FEUA turned out to be prominently high and the SLC22A12 mutation was detected. Therefore, patients with an accidental finding of hypouricemia, regardless of U_UA/U_Cr value, should be cautiously evaluated using FEUA. Molecular analysis should also be considered sequentially if needed. In addition, as incidental renal stone coexisted in the patient, unexplained renal stones need close inspections since nephrolithiasis might occur in 10% of patients with SLC22A12 mutations and in 40% of SLC2A9 mutations [13]. Since lab tests and genetic evaluations of the patient’s grandparents were not performed, pedigree analysis was not able to be done further. Additional evaluation of his family members could have made the trait and heritability of the disease more clear.

Table 2.

Reported cases of idiopathic renal hypouricemia with SCL22A12 mutations, homozygous W258X, in Korea

Low level of uric acid, an effective antioxidant acting as a vasodilator, and anaerobic exercises triggering vasoconstriction have a negative synergistic effect on glomerular filtration rate [11]. Thus, sudden onset of AKI can occur a few hours or days after strenuous physical exercises and within the same context, episodes of acute gastroenteritis may cause AKI in patients with renal hypouricemia. Accordingly, in Japan, it is asserted that screening for iRHUC detection using serum uric acid should be done before strenuous physical education classes [12].

There has been a lack of attention for hypouricemia so far because it rarely shows symptoms or requires immediate treatment. Among SLC22A12 mutations, the predominant cause of iRHUC, only few are confirmed with functional significance [18]. However, the W258X mutation, which is relatively common in Korea, tends to express symptoms compared to other subtypes of SLC22A12 mutations. Therefore, most patients with iRHUC are at potential risks for AKI and nephrolithiasis. As the serum uric acid level shows the lowest level between 2.2 and 2.5 mg/dL at 2–3 months of age and increases with age [20], children with uric acid level under 2.0 mg/dL should all be excluded from iRHUC.

In short, the current case reports a 7-year-old boy with nonspecific symptoms diagnosed iRHUC as early as before exposure to strenuous physical activities. Also, this report suggests that FEUA, with molecular analysis according to needs, should be done to all patients with hypouricemia to prevent delayed diagnosis and repetitive AKI which might occur.

Article information Continued